DR. ANTABHA BANDYOPADHYAY

Dr. RAHUL PRASAD, Dr..BIBHA KUMARI, Dr.Deepti Tiwari

Abstract

Aim: To relate OCT biomarkers like External limiting membrane (ELM) integrity, PROS (photoreceptor outer segment) length and thickness, ellipsoid zone (EZ) integrity etc. with visual acuity after bevacizumab in DME.

Method: prospective study of 50 patients (naive eyes; fovea involving DME). Subfoveal OCT was performed before, at 6 weeks and 3 months post-treatment. Biomarkers like PROS thickness and continuity, subfoveal continuity & integrity of EZ and ELM, sub retinal fluid, outer and inner nuclear layer cysts, high reflective foci location were evaluated; each marker was compared with visual acuity.

Result: DME resolved in 35 out of 50 patients. As per Statistical analysis, pre-treatment PROS thickness and EZ & ELM integrity depicted best correlation with post-treatment best-corrected visual acuity (p<0.05). Conclusion: OCT helps to assess diabetic retinopathy at early stage and the biomarkers used in this study, predict good visual outcome in DME patients treated with bevacizumab.